Drug Profile
Lerodalcibep - LIB Therapeutics
Alternative Names: LIB-003Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator LIB Therapeutics
- Class Antihyperlipidaemics; Recombinant fusion proteins
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypercholesterolaemia
Most Recent Events
- 19 Mar 2024 National Medical Products Administration (NMPA) approves clinical trial application for lerodalcibep in China
- 19 Mar 2024 LIB Therapeutics and Hasten Biopharmaceuticals plan clinical trials in Hypercholesterolaemia in China
- 13 Feb 2024 LIB Therapeutics announces intention to submit BLA to the US FDA for Hypercholesterolaemia in the first half of 2024